JP2011509246A5 - - Google Patents

Info

Publication number

JP2011509246A5

JP2011509246A5 JP2010540656A JP2010540656A JP2011509246A5 JP 2011509246 A5 JP2011509246 A5 JP 2011509246A5 JP 2010540656 A JP2010540656 A JP 2010540656A JP 2010540656 A JP2010540656 A JP 2010540656A JP 2011509246 A5 JP2011509246 A5 JP 2011509246A5

Authority

JP

Japan

Prior art keywords

antibody

item

cancer

her2

egfr

Prior art date

2008-12-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 41
• 201000011510 cancer Diseases 0.000 claims description 40
• 101001013022 Homo sapiens Migration and invasion enhancer 1 Proteins 0.000 claims description 39
• 102100029624 Migration and invasion enhancer 1 Human genes 0.000 claims description 39
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 27
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 27
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 26
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 26
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 26
• 239000012634 fragment Substances 0.000 claims description 23
• 206010006187 Breast cancer Diseases 0.000 claims description 18
• 208000026310 Breast neoplasm Diseases 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 17
• 229940124597 therapeutic agent Drugs 0.000 claims description 17
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
• 239000000427 antigen Substances 0.000 claims description 10
• 102000036639 antigens Human genes 0.000 claims description 10
• 108091007433 antigens Proteins 0.000 claims description 10
• 239000002246 antineoplastic agent Substances 0.000 claims description 10
• 229940127089 cytotoxic agent Drugs 0.000 claims description 10
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
• 229930012538 Paclitaxel Natural products 0.000 claims description 5
• 229940009456 adriamycin Drugs 0.000 claims description 5
• 229960001592 paclitaxel Drugs 0.000 claims description 5
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
• 206010005003 Bladder cancer Diseases 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
• 229960005395 cetuximab Drugs 0.000 claims description 4
• 208000029742 colonic neoplasm Diseases 0.000 claims description 4
• 201000007270 liver cancer Diseases 0.000 claims description 4
• 208000014018 liver neoplasm Diseases 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 201000002528 pancreatic cancer Diseases 0.000 claims description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
• 229960000575 trastuzumab Drugs 0.000 claims description 4
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
• 229960004562 carboplatin Drugs 0.000 claims description 3
• 190000008236 carboplatin Chemical compound 0.000 claims description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
• 229960004316 cisplatin Drugs 0.000 claims description 3
• 229960003668 docetaxel Drugs 0.000 claims description 3
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
• 229960005277 gemcitabine Drugs 0.000 claims description 3
• 230000005855 radiation Effects 0.000 claims description 3
• 229940063683 taxotere Drugs 0.000 claims description 3
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
• 229960002066 vinorelbine Drugs 0.000 claims description 3
• 230000037396 body weight Effects 0.000 claims description 2
• 238000000034 method Methods 0.000 description 124
• 210000004027 cell Anatomy 0.000 description 40
• 230000014509 gene expression Effects 0.000 description 17
• 241000124008 Mammalia Species 0.000 description 5
• 238000002965 ELISA Methods 0.000 description 4
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 4
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 239000012472 biological sample Substances 0.000 description 4
• 238000003364 immunohistochemistry Methods 0.000 description 4
• 238000000099 in vitro assay Methods 0.000 description 4
• 238000003752 polymerase chain reaction Methods 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1